Many transplant programs are reluctant to use organs from deceased donors designated as "PHS increased risk" due to misconceptions regarding the quality of those organs. This study evaluated the impact of PHS increased risk donors on patient and allograft survival in pediatric patients undergoing liver transplantation. Retrospective analysis of the UNOS database from January 2005 through September 2017 revealed 5615 pediatric patients who underwent isolated liver transplantation; of these, 5057 patients received primary isolated liver transplants and 558 patients received isolated liver retransplants. PHS increased risk organs were used in 6.7% and 5.4% of the children receiving primary isolated and retransplant livers, respectively. Cox proportional hazards models adjusted for donor and recipient characteristics determined the relative risk of PHS status on allograft and patient survival. Sicker children (those in ICU [P < .001] and on life support [P = .04]) were more likely to receive PHS increased risk donor organs. There were no differences in overall patient (P = .61) or allograft (P = .68) survival between pediatric patients receiving PHS positive vs PHS negative deceased donor organs; adjusted models also demonstrated no statistically significant differences in patient or allograft survival. Excellent patient and allograft survival can be accomplished with PHS increased risk organs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/petr.13712 | DOI Listing |
JMIR Form Res
January 2025
Center for Cancer Health Equity, Rutgers Cancer Institute, New Brunswick, NJ, United States.
Background: Cervical cancer disparities persist among minoritized women due to infrequent screening and poor follow-up. Structural and psychosocial barriers to following up with colposcopy are problematic for minoritized women. Evidence-based interventions using patient navigation and tailored telephone counseling, including the Tailored Communication for Cervical Cancer Risk (TC3), have modestly improved colposcopy attendance.
View Article and Find Full Text PDFKlin Mikrobiol Infekc Lek
September 2023
Clinic of Infectious Diseases, Faculty of Medicine, Masaryk University, University Hospital Brno, Czech Repubic, e-mail:
The rapid advancement of modern pharmacological and surgical therapeutic interventions is often accompanied by potential disruptions to the immune system, both permanent and transient. Consequently, life-threatening infectious complications may emerge, which were either absent or exceedingly rare in the past. Observational studies have identified pneumocystis and cytomegalovirus pneumonia as one of the most prevalent coinfections.
View Article and Find Full Text PDFKlin Mikrobiol Infekc Lek
September 2023
Clinic of Infectious Diseases, Faculty of Medicine, Masaryk University, University Hospital Brno, Czech Repubic, e-mail:
In parallel with the introduction of modern therapeutic and pharmacological interventions that have successfully resolved many diseases and conditions, previously deemed incompatible with life, there has been a significant increase in the number of patients experiencing secondary immunodeficiency. As a result, these patients are highly susceptible to various opportunistic infections. Among these infections, pneumocystis pneumonia (PCP) stands out as one of the most frequent and potentially life-threatening ones, necessitating prompt diagnosis and treatment.
View Article and Find Full Text PDFKlin Mikrobiol Infekc Lek
March 2024
Department of Microbiology, Olomouc University Hospital, Czech Republic, e-mail:
Objectives: Staphylococcus aureus is part of the human microbiota, but at the same time, it is capable of causing a wide range of diseases. Due to the ever-increasing resistance to antimicrobial agents and the existence of methicillin-resistant S. aureus (MRSA) strains, there is a real possibility of carrying even this resistant bacterium, which can subsequently cause a severe infection.
View Article and Find Full Text PDFImportance: Fragility fractures result in significant morbidity.
Objective: To review evidence on osteoporosis screening to inform the US Preventive Services Task Force.
Data Sources: PubMed, Embase, Cochrane Library, and trial registries through January 9, 2024; references, experts, and literature surveillance through July 31, 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!